An update from Cellectis SA ( (CLLS) ) is now available.
On May 6, 2025, Cellectis announced that it will release its first-quarter financial results for 2025 on May 12, 2025, after the US market closes. The company will not host a conference call to discuss these results, but its investor relations team is available for inquiries. This announcement highlights Cellectis’ ongoing commitment to transparency and communication with its stakeholders, reinforcing its position in the biotechnology industry.
Spark’s Take on CLLS Stock
According to Spark, TipRanks’ AI Analyst, CLLS is a Neutral.
Cellectis SA’s stock score is influenced by its strong strategic collaborations, notably with AstraZeneca, which enhance its financial stability and extend its cash runway. However, the company’s ongoing challenges with profitability and mixed technical signals weigh down the overall score. The positive earnings call sentiment and future clinical trial advancements are significant positives, whereas current valuation metrics and profitability issues are key concerns.
To see Spark’s full report on CLLS stock, click here.
More about Cellectis SA
Cellectis is a clinical-stage biotechnology company that leverages its pioneering gene-editing platform to develop life-saving cell and gene therapies. The company focuses on an allogeneic approach for CAR T immunotherapies in oncology, offering off-the-shelf and ready-to-use gene-edited CAR T-cells for cancer treatment. Cellectis also develops gene therapies for other therapeutic indications and controls the cell and gene therapy value chain from start to finish with its in-house manufacturing capabilities. Headquartered in Paris, France, with locations in New York and Raleigh, NC, Cellectis is listed on the Nasdaq Global Market and Euronext Growth.
Average Trading Volume: 343,901
Technical Sentiment Signal: Sell
Current Market Cap: $118.2M
For a thorough assessment of CLLS stock, go to TipRanks’ Stock Analysis page.